Targeting Disease at the Nuclear Pore
Karyopharm Therapeutics is an innovation-driven pharmaceutical company focused on the discovery, development, and commercialization of medicines with the goal of improving the lives of patients with cancer.

SINE Technology

Karyopharm is the industry leader in oral Selective Inhibitor of Nuclear Export (SINE) technology, developed to address a fundamental mechanism of oncogenesis.

Scientist doctor looking at sample in test tube

Pipeline

Our drug pipeline includes 4 unique investigational medicines targeting both hematologic malignancies and solid tumors.

Press Releases

August 6, 2019
Karyopharm Reports Second Quarter 2019 Financial Results and Highlights Recent Company Progress
August 1, 2019
Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Targeting Disease at the Nuclear PoreKaryopharm Therapeutics is an innovation-driven pharmaceutical company focused on the discovery, development, and commercialization of medicines with the goal of improving the lives of patients with cancer.

SINE Technology

Pipeline

Press Releases

Join The Karyopharm Team

Targeting Disease at the Nuclear Pore
Karyopharm Therapeutics is an innovation-driven pharmaceutical company focused on the discovery, development, and commercialization of medicines with the goal of improving the lives of patients with cancer.